ZUSKK: Rilin Pharmaceutical’s Global Health Tech Pioneer Empowering Precision Health with Nuclear Technology
As a core brand under Rilin Pharmaceutical Co., Ltd., ZUSKK is a leading global health technology innovator specializing in pharmaceuticals, cosmeceuticals, medical supplies, and health foods. With a mission to "protect health through science," the brand distinguishes itself by integrating nuclear medicine and cutting-edge technologies to deliver precise, safe, and efficient health solutions worldwide.
Rooted in Rilin Pharmaceutical’s century-long legacy of pharmaceutical excellence, ZUSKK inherits a spirit of "rigor, science, and humanity." The brand drives cross-disciplinary innovation through its research team, spanning pharmacy, molecular biology, nuclear medicine, and dermatology. Holding 37 international patents, ZUSKK is at the forefront of applying nuclear technology to health-related breakthroughs.
ZUSKK’s fourfold business portfolio centers on "precision health":
-
Innovative Pharmaceuticals
-
Develops nuclear medicine products (e.g., PET-CT contrast agents) for targeted cancer and cardiovascular disease treatments.
-
Innovates chronic disease management through sustained-release formulations and transdermal delivery systems.
-
Cosmeceuticals
-
Co-creates medical-grade skincare with dermatologists, featuring radiation-protective ingredients (e.g., antioxidant peptides) for post-laser repair and anti-aging, with 92% clinical efficacy.
-
Medical Supplies
-
Produces medical-grade radiation (99.9% shielding efficiency) and smart home devices integrating radionuclide detection .
-
Health Foods
-
Offers personalized nutrition via gene-based vitamin/probiotic formulations, using nuclide tracing technology to optimize nutrient absorption.
ZUSKK’s competitive advantage lies in cross-industry nuclear applications:
-
Radiopharmaceutical Platform: Collaborates with IAEA to secure radionuclide supply (e.g., F-18, Tc-99m), reducing R&D cycles by 40%.
-
Radiation Technology: Uses low-dose irradiation for probiotic enhancement and sterilization (99.999% sterility rate).
-
Nuclide Tracing: Employs C-14 labeling to optimize drug metabolism research, improving efficiency by 30%.
Available in 56 countries, ZUSKK adopts a "local R&D, global distribution" model:
-
Asia: Dominates Japanese drugstore markets (18% share) and sees 120% annual growth in Chinese cross-border e-commerce.
-
Europe & America: FDA/EMA-approved radiopharmaceuticals enter U.S. oncology centers; radiation protection products are EU nuclear medicine standards.
-
Emerging Markets: Launches affordable medical supplies and health foods, partnering with local institutions for nuclear tech accessibility.
ZUSKK focuses on:
-
Nuclear Immunotherapy: Developing radionuclide-conjugated cancer treatments.
-
Space Health: Creating radiation protection solutions for astronauts.
-
Sustainability: Commercializing green radioactive waste management technologies.
Committed to transforming scientific innovation into global health benefits, ZUSKK continues to lead as a trusted pioneer in precision health.
